Bednaríková D, Kocák I
Privátní kozní ambulance, Brno.
Klin Onkol. 2010;23(5):300-5.
At present, the dermal toxicity of anti-cancer drugs is ever more apparent in cancer patients. This phenomenon appears, in particular, in relation to the increased administration of targeted anti-cancer treatment, especially of monoclonal antibodies and tyrosinkinase inhibitors (TKI), towards various receptors of growth factors which are applied in the ethiopathogenesis of a tumour cell. Our article focuses on the palmoplantar erythrodysesthesia syndrome, designated also as the hand-foot skin reaction (HFSR), which most frequently occurs in patients treated with TKI sorafenib and sunitinib. Developed HFSR may be a strongly perceived adverse effect for patients and may lead to dose intensity reduction in the targeted treatment, or to its interruption if necessary. However, a correct approach from the oncologist and dermatologist, including instructions to be provided to the patient on how to prevent a serious grade of HFSR from being developed, may ensure a smooth anti-cancer treatment and a satisfactory quality of life for cancer patients.
目前，抗癌药物的皮肤毒性在癌症患者中愈发明显。这种现象尤其出现在针对肿瘤细胞发病机制中应用的各种生长因子受体的靶向抗癌治疗增加时，特别是单克隆抗体和酪氨酸激酶抑制剂（TKI）的使用增加。我们的文章聚焦于手足红斑感觉异常综合征，也称为手足皮肤反应（HFSR），它最常发生在接受TKI索拉非尼和舒尼替尼治疗的患者中。严重的HFSR对患者来说可能是一种强烈感受到的不良反应，可能导致靶向治疗的剂量强度降低，必要时甚至会导致治疗中断。然而，肿瘤学家和皮肤科医生采取正确的方法，包括向患者提供如何预防严重程度的HFSR发生的指导，可确保癌症患者的抗癌治疗顺利进行，并使其生活质量令人满意。
